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In ischemic stroke patients, the incidence of prior cancer can be up to 16%,1 both diseases causing 
significant disability and loss of productive life-years. In a recent US-based nationwide registry 
study, about 10% of all hospitalized ischemic stroke patients had comorbid cancer, with a slight 
rise in this rate over the last decade.2 Stroke patients diagnosed with occult cancer are usually 
older with men being at a higher risk of having comorbid cancer.3,4 In addition, probability of 
cancer diagnosis after stroke is associated with smoking, elevated D-dimer, elevated C-reactive 
protein (CRP), and anemia on admission.3,4 In a Swedish nationwide follow-up study, patients 
with cancer developed ischemic stroke 2.2 times more often than their age-and sex-matched non-
cancer control population during a six months follow-up. Although the risk of stroke decreased 
rapidly, it remained elevated even over 10 years.5 A Danish registry-based case-control study with 
over 264,000 cancer patients also showed an approximately 2-fold risk for ischemic stroke in 
occult cancers.6 No solid data exist on exact prevalence of different cancer types in ischemic 
stroke patients. However, lung, pancreatic and colorectal cancers seem to have a higher 
association with ischemic stroke, perhaps due to their aggressiveness.7 Other reported common 
cancer types include breast, urogenital and prostate cancers.7 
Cancer and ischemic stroke share multiple common risk factors such as age, obesity, and smoking. 
Thus, cancer patients are not immune to common causes of ischemic stroke such as atrial 
fibrillation, large-artery atherosclerosis and small-vessel occlusions. Despite that, up to 50% of 
ischemic strokes occurring in patients harboring a cancer are considered cryptogenic. However, 
these strokes usually have an embolic pattern and it has been suspected that they are actually 
cardioembolic manifestations of cancer-mediated hypercoagulopathy or even caused by a 
paradoxical embolism.8 Cancer can also cause marantic (non-bacterial) endocarditis, mechanical 
compression of critical vessels, anemia, and tumor embolism.8,9 Other potential mechanisms that 
increase the risk of ischemic stroke in the presence of cancer include endothelium dysfunction and 
abnormalities in turbulence in abnormal blood vessels. It is essential to keep in mind that also 
cancer treatments, such as surgery, radiotherapy, and chemotherapy, can increase the risk of 
subsequent stroke by leading to thrombin generation, embolism, and radiation-induced 
vasculopathy.8,9
In cancer-associated ischemic stroke, several factors, such as elevated D-dimer and specific cancer 
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deterioration, recurrent strokes and other types of thromboembolism.10-12 Furthermore, ischemic 
stroke patients with active cancer have a higher risk for both short-term and long-term mortality. 
This risk is even higher in cancer patients with severe strokes, metastases, diabetes, elevated CRP 
and higher D-dimer levels.8
Hence, patients harboring an active cancer and admitted with an acute stroke is a common 
scenario. In this issue of Acta Neurologica Scandinavica, Tybjerg and colleagues investigated the 
prevalence and risk of occult cancer in stroke by using national registries in Denmark.13 They 
identified all patients >40 years old with either ischemic or hemorrhagic stroke from their national 
stroke registry and matched them to the general Danish population with a 1:10 ratio 
(approximately 86,000 stroke patients and 860,000 stroke-free control subjects). Linking to a 
national cancer registry, they found that cancer prevalence (per 1,000) was clearly higher among 
stroke patients: stroke vs. background population 25.0/15.8 in women and 29.8/20.4 in men. As in 
prior studies, the prevalence of cancer was highest in the oldest patients aged over 70 years (35.6 
in women and 42.4 in men per 1,000). Risk of occult cancer was 54% higher in stroke patients, 
increasing further with age, male gender, smoking, and diabetes. This study brings an interesting 
addition to the current body of evidence, providing useful data on numbers needed to screen 
(NNS) cancer in stroke patients. NNS in order to detect cancer in these stroke patients was 40 for 
women and 34 for men compared to the stroke-free background population, NNS 63 for women 
and 49 for men.13
A relevant question is whether to search for an underlying cancer in the first place in a stroke 
patient and which cancers are worth searching for first. No international guideline included a 
recommendation on this topic yet. A suspicion of cancer-associated ischemic stroke should be 
raised especially in patients with a stroke of undetermined source, persistently elevated markers of 
coagulation (most notably D-dimer), weight loss, active smoking or history of smoking, fatigue, 
anemia, elevated CRP and/or erythrocyte sedimentation rate (ESR), low hematocrit, and patients 
with embolic stroke pattern in brain imaging.7 Thus, in a high clinical suspicion of a cancer-
associated stroke, etiological investigations could include broad laboratory assessment, including 
D-dimer levels, as well as whole-body computer tomography imaging and carefully selected 
tumor markers, such as CA125 and CA199 to exclude lung cancer.7 If needed, further 
investigations should include positron emission tomography with the glucose analog 2-[18F]fluoro-
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tests and/or colonoscopy with biopsies. However, there is still a clear need for guidelines and a 
cancer probability score regarding which stroke patients should undergo cancer screening and 
what the extent of such a screening might be.
Another relevant clinical question is how to manage stroke patients with comorbid cancer to avoid 
recurrent strokes, both ischemic and hemorrhagic. Thus far, only a few studies have addressed the 
issue of an optimal secondary prevention in cancer patients with an acute ischemic stroke. The 
TEACH pilot study of 20 ischemic stroke patients with an active cancer comparing treatment with 
enoxaparin and aspirin showed that the cumulative rates of thromboembolic events, major 
bleeding, and survival rates were similar between the treatment arms.14 Another study with 48 
cryptogenic ischemic stroke patients with an active cancer, that compared new oral anticoagulants 
and low-molecular weight heparin in secondary prevention, showed similar clinical outcomes and 
safety between the two groups.15 In an exploratory analysis of the NAVIGATE ESUS trial, among 
7213 randomized patients with an embolic stroke of undetermined source, 543 (7.5%) reported a 
history of cancer. Of these, 254 were randomized to rivaroxaban and 289 to aspirin. Both 
treatment arms had similar risk of recurrent ischemic stroke and all-cause mortality, but aspirin 
seemed safer than rivaroxaban regarding major bleeding, consistent with the overall trial results.16 
Larger prospective randomized trials comparing safety and efficacy of various anticoagulant and 
antiplatelet agents are warranted.
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